Specialization
Cancer immunology, Immunotherapy, Multiple myeloma
-
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Korst, C. L. B. M., Tahri, S., Duetz, C., Bruins, W. S. C., de Jonge, A. V., de Jong, M. E., Fokkema, C., Smits, F., Groen, K., Verkleij, C. P. M., Frerichs, K. A., Papazian, N., van Duin, M., van Beek, G., Hoogenboezem, R., Baardemans, T., Dal Collo, G., Stoetman, E. C. G., Cosovic, M. & Twickler, I. & 15 others, , 19 Jun 2025, In: Blood. 145, 25, p. 3007-3014 8 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma
Bruins, W. S. C., Rentenaar, R., Newcomb, J., Zheng, W., Ruiter, R. W. J., Baardemans, T., Poma, E., Moore, C., Robinson, G. L., Lublinsky, A., Zhang, Y., Syed, S., Milhollen, M., Dash, A. B., van de Donk, N. W. C. J., Groen, R. W. J., Zweegman, S. & Mutis, T., 1 Nov 2024, In: HemaSphere. 8, 11, e70039.Research output: Contribution to journal › Article* › Academic › peer-review
-
Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma
de Jonge, A. V., Bruins, W. S. C., Duetz, C., Korst, C. L. B. M., Rentenaar, R., Cosovic, M., Eken, M., Kersten, M.-J., Sandberg, Y., van Rijn, R. S., Fijnheer, R., Mutsaers, P., Vergote, V. K. J., Issa, D., Beeker, A., Bilgin, Y. M., Visser, O., van Werkhoven, E., Roemer, M. G. M. & Chamuleau, M. E. D. & 1 others, , 1 Nov 2024, In: Haematologica. 109, 11, p. 3760-3761 2 p.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications